Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02158052

Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This pilot trial offers the unique opportunity for both the treatment of multiple myeloma or other hematologic disorder for which hematopoietic stem cell transplantation would be ordinarily indicated and the reversal of end-stage renal failure, while avoiding the risks associated with long-term standard anti-rejection therapy used in renal transplantation. The primary objectives of this study are to assess renal allograft tolerance (that is, the acceptance of the kidney without the need for anti-rejection therapy), assess anti-tumor response rates in multiple myeloma and other malignancies, and assess complication rates for genetically (HLA) matched related donor combined

Status: 
Recruiting
Study Date: 
Sun, 02/01/2015 to Thu, 02/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Tacrolimus Tacrolimus starting on Day -1 Drug: Anti-thymocyte globulin 20 mg/kg IV on Days -3, -1, +1, +3 Procedure: Kidney transplant On Day 0 the renal transplant is performed according to standard surgical techniques. Drug: Bone marrow transplant from a related donor Donor bone marrow (> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Radiation: Total body irradiation 400 centigray (200 cGy X 2) on day -1